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ABSTRACT
Objective Independent temporal external validation 
of the improving partial risk adjustment in surgery 
model (PRAIS-2) to predict 30- day mortality in patients 
undergoing paediatric cardiac surgery.
Design Retrospective analysis of prospectively collected 
data.
Setting Paediatric cardiac surgery.
Intervention PRAIS-2 validation was carried out using a 
two temporally different single centre (Bristol, UK) cohorts: 
Cohort 1 surgery undertaken from April 2004 to March 
2009 and Cohort 2 from April 2015 to July 2019. For each 
subject PRAIS-2 score was calculated according to the 
original formula.
Participants A total of 1352 (2004-2009) and 1197 
(2015-2019) paediatric cardiac surgical procedures 
were included in the Cohort 1 and Cohort 2, respectively 
(median age at the procedure 6.3 and 7.1 months).
Primary and secondary outcome measures PRAIS-2 
performance was assessed in terms of discrimination by 
means of ROC (receiver operating characteristic) curve 
analysis and calibration by using the calibration belt 
method.
Results PRAIS-2 score showed excellent discrimination 
for both cohorts (AUC 0.72 (95%CI: 0.65 to 0.80) and 0.88 
(95%CI: 0.82 to 0.93), respectively). While PRAIS-2 was 
only marginally calibrated in Cohort 1, with a tendency to 
underestimate risk in lowrisk and overestimate risk in high 
risk procedures (P- value = 0.033), validation in Cohort 2 
showed good calibration with the 95% confidence belt 
containing the bisector for predicted mortality (P- value 
= 0.143). We also observed good prediction accuracy in 
the non- elective procedures (N = 483;AUC 0.78 (95%CI 
0.68 to 0.87); Calibration belt containing the bisector (P- 
value=0.589).
Conclusions In a single centre UK- based cohort, PRAIS-2 
showed excellent discrimination and calibration in 
predicting 30- day mortality in paediatric cardiac surgery 
including in those undergoing non- elective procedures. 
Our results support a wider adoption of PRAIS-2 score in 
the clinical practice.
INTRODUCTION
Congenital heart diseases (CHDs) are the 
most common birth defect affecting between 
6 and 8 per 1000 of live born children in 
middle- income and high- income coun-
tries.1 2 Around 5000 paediatric cardiac 
surgical procedures are performed each year 
in the UK. Despite overall mortality being low 
(3%), there is notable variation in mortality 
rates between centres. Mortality rates, and 
variation between centres, are monitored by 
public and healthcare regulatory bodies as 
part of assessing the quality of care provided 
by the centres. In order to monitor a centre’s 
quality of care and performance and make 
fair comparisons between centres in terms of 
mortality following paediatric cardiac surgery, 
it is essential to take account of differences 
in case mix across centres.3 This requires 
accurate risk stratification. However, CHD 
includes a large spectrum of diagnoses with a 
wide range of surgical procedures performed 
in the context of a relatively small number of 
patients. These characteristics make risk strat-
ification extremely challenging.
Several methods that aim to provide an 
objective risk assessment for taking account 
of case mix when assessing centre perfor-
mance have been developed. These include 
Strengths and limitations of this study
 ► A strength of the present study is that data were 
prospectively collected as part of the UK National 
Congenital Heart Disease Audit, and as such, they 
have undergone continuous and inclusive system-
atic validation that includes the review of a sample 
of case notes by external auditors to ensure coding 
accuracy.
 ► We used a recently proposed method (calibration 
belt) that does not require patients to be categorised 
according to risk percentile but rather provides a 
risk function across all risk value with 95% CI pro-
viding a measure of uncertainty/imprecision.
 ► A key limitation of this study is that the sample size 
is relatively small and considerably smaller than the 
cohort used to develop PRAIS-2.
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consensus- based methods, such as the Risk Adjustment 
for Congenital Heart Surgery-1 Categories (RACHS-1 
Categories)4 and Aristotle,5 and more recently empir-
ical research- based methods, such as The Society of 
Thoracic Surgeons–European Association for Cardio- 
Thoracic Surgery Congenital Heart Surgery Mortality 
Categories (STAT Mortality Categories),6 the Society 
of Thoracic Surgeons Congenital Heart Surgery Data-
base (STS- CHSD) Mortality Risk Model for Congenital 
Cardiac Surgery,7–9 and the partial risk adjustment in 
surgery (PRAIS),10 which has been developed in the UK 
and proposed for measuring between centre variation 
in mortality across the UK. The most recently updated 
version, PRAIS-2,11 was developed to predict 30- day 
mortality using data from the UK National Congenital 
Heart Disease Audit (NCHDA).12 In comparison to 
PRAIS, PRAIS-2 included more detailed information 
about acuity, diagnosis and comorbidities and was shown 
to have better discrimination and calibration than the 
original PRAIS.13 However, adoption of PRAIS-2 into 
clinical practice is still limited and this has been partially 
attributed to the lack of external independent valida-
tion other than the one presented by the authors in 
the original paper.14 That validation used data from the 
same UK dataset but was undertaken on a temporally 
independent subcohort (figure 1). While such valida-
tion within a study is important, using the same cohort 
(and same group of investigators) can result in risk of 
optimism bias, which would tend to exaggerate risk 
stratification accuracy in comparison to findings from 
independent cohorts and investigators.15 16 Moreover, 
prediction models can present significant calibration 
drift due to temporal and geographic differences in case 
mix, patients characteristics and surgical technique; 
the impact of this on the performance of PRAIS-2 is 
unknown.17 18 Lastly, as the data used to develop PRAIS-2 
did not include information on whether the procedures 
were elective or conducted as non- elective (emergen-
cies, urgency and salvage), it was not possible to deter-
mine whether performance was similar in both of these 
situations. It is not implausible that stratification accu-
racy will differ between the two.
The purpose of this study was to perform an external 
independent validation of the PRAIS-2 score in a cohort 
from a single tertiary paediatric UK centre (in Bristol, 
South West England). This single UK centre contributed 
to the cohort in which PRAIS-2 was originally developed, 
but with data from different time periods than used 
here. In this study, we determine performance discrimi-
nation separately in two Bristol Heart Institute cohorts: 
(1) procedures performed earlier than those used in the 
initial development and validation of PRAIS-2 (Cohort 
1) and (2) procedures performed after those used 
in the initial development and validation of PRAIS-2 
(Cohort 2). To explore possible calibration drift, we have 
compared calibration of the model prediction between 
three Bristol Heart Institute cohorts; procedures under-
taken 2004–2009 (Cohort 1), 2009–2015 (Cohort over-
lapping the dataset included in PRAIS-2 development) 
and 2015–2019 (Cohort 2). In a subsample, we were also 
able to undertake the first (exploratory) analysis of how 
well PRAIS-2 performs in those undergoing non- elective 
procedures.
Figure 1 ROC (receiver operating characteristic curve) curve for PRAIS-2 in the independent Cohort 1, 2 and Overlapping 
Cohort.
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METHODS
The study complies with the Declaration of Helsinki. As 
this analysis came under clinical audit/quality of care 
assessment and all data were anonymised following the 
governance criteria of the NHS, the institutional review 
board agreed informed consent was not required.
Patient and public involvement
This research was done without patient and public 
involvement.
Data source
Data were obtained from the Bristol dataset which is part 
of the NCHDA within the National Institute of Cardio-
vascular Outcomes Research (NICOR). As such, the 
data used here have undergone continuous and inclu-
sive systematic validation, which includes the review of a 
sample of case notes by external auditors to ensure coding 
accuracy.12 Table 1 summarises the data sources used in 
this study and their relationship to the UK National data 
used in the development of PRAIS-2.
The entire (ie, including all three cohorts used in 
any analyses) Bristol data consisted of 4886 paediatric 
cardiac surgical procedures (defined as surgery on 
the heart or great vessel in patients aged <16 years old, 
excluding catheter procedures and trivial/minor proce-
dures) performed between April 2004 and July 2019. 
Procedures with missing information on mortality (133), 
one or more of the variables used in the calculation of 
PRAIS-2 calculation (371) or both (9) were excluded. 
Procedures with missing information on one or more of 
the variables used to calculate PRAIS-2 showed a higher 
rate of 30- day mortality (online supplemental table S1). 
For those with missing data on one or more of the vari-
ables used to calculate PRAIS-2, the variables that were 
available suggested that they had higher risk profiles 
than those with no missing variables, both in the whole 
study data (online supplemental table S1) and when 
analysed in the three separate temporal cohorts (online 
supplemental tables S2–S4). For example, in those with 
at least one missing variable (n=371), the proportion 
with severe illness was 22.9%, whereas in those with no 
missing variables (n=4373) it was 7%. The same results 
in Cohort 1 were 15.5% and 0%, in the overlapping with 
PRAIS-2 discovery were 0% and 3.3% and in Cohort 2 
were 18.5% and 55.6%. The remaining 4373 (90% of the 
4886 eligible) procedures were included in the analysis. 
PRAIS-2 was developed using national data (including 
that from the Bristol cohort) from patients undergoing 
procedures between April 2009 and March 2015. In these 
analyses, we use Bristol data from April 2004 to March 
2009 (Cohort 1) and April 2015 to July 2019 (Cohort 2) as 
independent external validation. While we acknowledge 
that treatments and mortality rates have changed since 
2004, and the first validation set may not reflect contem-
porary practice, we would expect this to primarily affect 
model calibration; finding good discrimination for this 
earlier set would support external validity and general-
isability of PRAIS-2. Seeing good discrimination across 
all time periods would provide valuable evidence about 
the generalisability of the PRAIS-2 model. In addition, 
we explored discrimination and calibration in the Bristol 
cohort that was also included in the national cohort to 
develop PRAIS-2, April 2009 to March 2015 (Overlap-
ping Cohort). This allows us to explore any evidence of 
geographical (centre) difference in stratification perfor-
mance and using all three cohorts to explore the extent 
of temporal calibration drift.
PRAIS-2 prediction score and its constituent variables
PRAIS-2 score is generated from a transformed logistic 
regression model of 30- day mortality following cardiac 
surgery.13 The model included the following periopera-
tive variables: age, weight, diagnosis, procedure group, 
type of procedure, whether or not there was definite 
univentricular heart function, additional cardiac risk 
factors, acquired comorbidity, congenital comorbidity, 
severity of illness and an additional coefficient for proce-
dures performed after 2013 (online supplemental table 
S1 shows the units or categories of each of these vari-
ables). The formula for the PRAIS-2 score (using the 
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where z is the logistic model function of the nine vari-
ables. In all analyses, we used the PRAIS-2 model (equa-
tion) that was recalibrated by the original authors after 
their internal validation (online supplemental equation 
1).
Outcome
The primary outcome was 30- day all- cause mortality. 
Information on mortality was obtained from the Office 
for National Statistics (ONS).
Statistical analysis
Continuous data were presented as medians with IQR. 
Categorical variables were presented as counts with 
percentages. We assessed the discriminative ability of the 
PRIAS-2 model to distinguish between children who did 
and did not die within 30 days using the area under the 
receiver operating characteristic curve (AUC) analysis19 
and its calibration by comparing observed to predicted 
30- day mortality rates for groups of procedures with 
different predicted levels of risk.14 20 21 Model perfor-
mance in the main analysis (Cohort 1 and Cohort 2) was 
also evaluated by reporting sensitivity, specificity, positive- 
likelihood and negative- likelihood ratios (LRP and LRN) 
and the positive and negative predictive values (PPV and 
NPV) using cut- off values that included 10%, 20%, 80% 
and 90% above the cut- off.22
Overall model calibration was assessed using the cali-
bration belt method. This method is based on a general-
isation of Cox’s regression modelling where the relation 
between the logits of the probability predicted by a model 
and of the event rates observed in a sample is repre-
sented by a polynomial function whose coefficients are 
fitted and its degree is fixed by a series of likelihood- ratio 
tests.23 Risk underestimation is suggested if the calibra-
tion belt with its 95% CI is above the bisector (perfect 
prediction line), while overestimation is indicated by the 
belt with its 95% CI being below the bisector. The cali-
bration belt method was accompanied by the Hosmer- 
Lemeshow χ2 goodness- of- fit test.24 Comparison of χ2 
were used to investigate the extent of calibration drift 
across different eras. All analyses were performed using 
R V.3.5.2 and the following packages: givitiR, ROCit, 
ggplot2, ResourceSelection.
RESULTS
The final study population consisted of 1352 procedures 
in Cohort 1 (median age (IQR) 6.3 (1.4–30.8)), 1197 
procedures in Cohort 2 (median age (IQR) 7.1 (2.2–
51.0)), which also included 483 non- elective procedures, 
and 1824 procedures in the Overlapping Cohort (median 
age (IQR) 5.9 (1.3–38.6)).
Table 2 shows procedures characteristics of the two 
external validation (Cohort 1 and Cohort 2) and the 
subgroup, from Cohort 2, who had non- elective proce-
dures, and the Overlapping Cohort. While the average 
PRAIS-2 score did not differ across the temporally different 
cohorts, we noticed a downward shift in mortality rate in 
the most recent Cohort 2.
The predicted risk in the external validation cohorts 
(Cohort 1 and Cohort 2), the Overlapping Cohort and 
the non- elective subset were 1.1%, 1.0%, 1.1.% and 2.9%, 
respectively, and the observed mortality was 2.4%, 1.9%, 
3.1% and 4.6%, respectively (online supplemental figure 
1).
In the Cohort 2 external validation analysis, the 
PRAIS-2 score showed good discrimination ability (AUC 
0.87; 95% CI 0.82 to 0.93, figure 1) and calibration 
between predicted and observed mortality across all risk 
categories with the 95% CI of calibration belt containing 
the bisector (p value=0.14 (figure 2; Hosmer and Leme-
show goodness- of- fit test χ2=8, df=8, p- value=0.5 (online 
supplemental table S6A). Sensitivity, specificity, LRP, 
LRN, PPV and NPB using different cut- off values of the 
prediction score are reported in table 3. Assuming safe 
effective interventions could reduce those identified at 
high risk of mortality, in this population we would want 
to correctly identify the majority of those at risk, that is, 
minimise false negative results by having a highly specific 
test, and we would want a positive test to have a high 
probability of identifying those most at risk (PPV). A 10% 
threshold maximises specificity (0.90) and maximised the 
PPV (although this is only 0.10). The 20% threshold also 
has high specificity (0.80) and a similar PPV (0.06) to the 
10% threshold.
In Cohort 1, PRAIS-2 showed a lower but still good 
discrimination ability (AUC 0.72 (95%CI 0.65 to 0.80, 
figure 1), compared with Cohort 1, but was poorly cali-
brated, with a tendency to underestimate risk in low- risk 
procedures and overestimate in high- risk procedures (p 
value=0.033, figure 2; Hosmer and Lemeshow goodness- 
of- fit test χ2=19, df=8, p value=0.02, online supplemental 
table S6b). Online supplemental table S7 shows the 
discrimination metrics for this cohort, with results similar 
to those found for Cohort 2 and shown in table 2.
In additional analyses to check that data from Bristol 
were not notably different to the main UK- wide develop-
mental cohort, we showed that the Overlapping Cohort 
also had good discrimination, with results similar to the 
whole developmental cohort (AUC 0.82 (95%CI 0.77 
to 0.88, figure 1). However, the model was only margin-
ally calibrated with a tendency to risk underestimation 
(figure 2). Hosmer and Lemeshow goodness- of- fit test 
χ2=16, df=8, p value=0.04 (online supplemental table 
S6c).
Considering calibration drift across all three temporally 
different cohorts, we observe modest improvement across 
all three cohorts such that the most recent cohort was 
the best calibrated. Specifically, the Hosmer- Lemeshow 
test χ2 decreased from 19 in Cohort 1, through 16 in the 
Overlapping Cohort to 8 in Cohort 2.
In the subgroup of non- elective procedures (a 
subgroup of Cohort 2 as these data were not available in 
the other two cohorts), the model showed good discrim-
ination, with AUC 0.78 (95% CI 0.68 to 0.87, figure 3) 
 on M
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Total number of procedures 1352 1197 483 1824
Age, year (median, IQR) 6.3 (1.4–30.8) 7.1 (2.2–51.0) 1.7 (0.3–5.0) 5.9 (1.3–38.6)
Weight, kg (median, IQR) 6.1 (3.4–12.5) 6.9 (3.9–15.5) 3.7 (3.1–5.3) 6.0 (3.6–13.4)
Diagnoses group, n (%)*
  GROUP 1 71 (5.3) 107 (8.9) 47 (9.7) 154 (8.4)
  GROUP 2 149 (11.0) 163 (13.6) 77 (15.9) 194 (10.6)
  GROUP 3 111 (8.2) 103 (8.6) 65 (13.5) 125 (6.9)
  GROUP 4 218 (16.1) 232 (19.4) 118 (24.4) 222 (12.2)
  GROUP 5 104 (7.7) 122 (10.2) 49 (10.1) 123 (6.7)
  GROUP 6 104 (7.7) 137 (11.4) 45 (9.3) 100 (5.5)
  GROUP 7 176 (13.0) 127 (10.6) 34 (7.0) 312 (17.1)
  GROUP 8 155 (11.5) 105 (8.8) 32 (6.6) 192 (10.5)
  GROUP 9 20 (1.5) <5 (<1) <5 (<1) 25 (1.4)
  GROUP 10 56 (4.1) 14 (1.2) 6 (1.2) 95 (5.2)
  GROUP 11 188 (13.9) 85 (7.1) 8 (1.7) 282 (15.5)
  Procedure group, n (%)*
  GROUP 1 <5 (<1) 31 (2.6) 22 (4.6) 28 (1.5)
  GROUP 2 29 (2.1) 11 (0.9) 10 (2.1) 33 (1.8)
  GROUP 3 107 (7.9) 46 (3.8) 34 (7.0) 84 (4.6)
  GROUP 4 99 (7.3) 103 (8.6) 73 (15.1) 114 (6.2)
  GROUP 5 239 (17.7) 228 (19.0) 126 (26.1) 344 (18.9)
  GROUP 6 148 (10.9) 53 (4.4) 36 (7.5) 180 (9.9)
  GROUP 7 21 (1.6) 45 (3.8) 17 (3.5) 50 (2.7)
  GROUP 8 86 (6.4) 100 (8.4) 12 (2.5) 126 (6.9)
  GROUP 9 20 (1.5) 16 (1.3) 5 (1.0) 26 (1.4)
  GROUP 10 36 (2.7) 35 (2.9) 7 (1.4) 70 (3.8)
  GROUP 11 36 (2.7) 19 (1.6) 8 (1.7) 57 (3.1)
  GROUP 12 32 (2.4) 64 (5.3) 1 (0.2) 50 (2.7)
  GROUP 13 87 (6.4) 68 (5.7) 5 (1.0) 103 (5.6)
  GROUP 14 38 (2.8) 43 (3.6) 7 (1.4) 55 (3.0)
  GROUP 15 217 (16.1) 144 (12.0) 11 (2.3) 275 (15.1)
  GROUP 20 156 (11.5) 191 (16.0) 109 (22.6) 229 (12.6)
  Bypass n (%) 903 (66.8) 911 (76.1) 273 (56.5) 1361 (74.6)
Univentricular heart 
category, n (%)
143 (10.6) 219 (18.3) 95 (19.7) 258 (14.1)
Severity of illness†, n (%) 0 (0.0) 222 (18.5) 203 (42.0) 86 (4.7)
Acquired comorbidity†, n 
(%)
9 (0.7) 207 (17.3) 132 (27.3) 94 (5.2)
Additional cardiac risk 
factors†, n (%)
58 (4.3) 82 (6.9) 56 (11.6) 52 (2.9)
Congenital comorbidity†, 
n (%)
173 (12.8) 343 (28.7) 143 (29.6) 274 (15.0)
PRAIS-2 (median, IQR) 0.0115 (0.0037–0.0258) 0.010 (0.004–0.027) 0.029 (0.011–0.068) 0.011 (0.003–0.027)
30- day mortality, n (%) 32 (2.4) 23 (1.9) 22 (4.6) 56 (3.1)
Continued
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and good calibration, with the bisector contained within 
the 95% confidence level of the calibration belt (p value 
0.61; figure 4 and Hosmer and Lemeshow goodness- of- fit 
test, χ2=10, df=8, p value=0.3; online supplemental table 
S6d). We were not able to conduct the analysis restricted 
to elective procedures as all but one patients survived to 
30 days following elective procedures.
DISCUSSION
Risk prediction models play an important role in current 
paediatric cardiac surgical practice because they allow 
meaningful comparison of outcomes between institutions 
by adjusting for differing case mix. Moreover, they can 
also give useful information for surgical decision- making, 
preoperative patient information and quality assurance 
measures. Before implementing a risk model in clinical 
practice, it is important to confirm its prediction ability 
with external validation.14 25
To our knowledge, PRAIS-2 has never undergone 
external validation other than that originally presented 
by the authors who developed the model. It is important 
that prediction models are validated by independent 
researchers, as well as in independent samples, before 
being adopted into clinical practice because authors 
evaluating the performance of their own model may 
tend to be overly optimistic in interpreting results or 
selective reporting.16 26 For this reason, we conducted an 
external validation study of PRAIS-2 in two cohorts from 
the paediatric cardiac surgical procedures cohort at the 
Bristol Royal Hospital for Children. Our findings show 
that in these two cohorts, which are independent (of the 
original cohort used to develop PRAIS-2), the PRAIS-2 
model has good discrimination and good calibration in 
the most recent (Cohort 2) cohort. That calibration was 
better in Cohort 2 than in the Overlapping Cohort was 
surprising as we might expect the cohort contributing 
to the development of PRAIS-2 to be the best calibrated. 
We speculate that the temporal improvement in calibra-
tion across all three cohorts from the same geographical 
region is likely to reflect changes over time in case mix, 
patient risk profile and improvement in perioperative 
care. While we saw an improvement in calibration over 
time, the amount of this was modest. However, a further 
validation of the PRAIS-2 in the coming years would be 
useful as marked drift could result in important levels of 
risk overestimation or underestimation.18
As PRAIS-2 was developed with data from across the 
UK and in our external validation we have only used data 
from Bristol, we wanted to make sure that prediction in 
Bristol was broadly consistent with the UK as a whole. We 
therefore explored the predictive accuracy of PRAIS-2 in 
the Bristol cohort that contributed to the original PRAIS-2 
development and found good discrimination, but the 
model was only marginally calibrated with a tendency to 
underestimate risk. It is not uncommon for calibration 













*As the diagnoses groups and procedure groups have lengthy text details, we have not provided them in the table; they can be found in 
online supplemental table 5.
†Exact number suppressed for disclosure control purposes.
‡Definitions of variables are given in online supplemental table 5.
Table 2 Continued
Figure 2 Calibration belt of PRAIS-2 in the independent Cohort 1, Cohort 2 and Overlapping Cohort.
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time. We are not able to determine variation in calibra-
tion between all of the different centres that contributed 
to the original PRAIS-2 development as data were not 
presented by centre in the original documentation of 
PRAIS-2 development.13
PRAIS-2 development excluded non- elective proce-
dures and so its accuracy in this group, or whether this 
would be a valuable predictor, is unknown. We demon-
strated that PRAIS-2 does have good discrimination 
and calibration in this higher risk subgroup. However, 
we acknowledge that our numbers were small for these 
analyses and this needs further exploration and valida-
tion in larger independent samples. We were not able 
to compare performance between those undergoing 
elective procedures and those undergoing non- elective 
procedures as the mortality rate was very low, resulting in 
only one death among those undergoing elective proce-
dures. This marked difference in mortality between elec-
tive and non- elective procedures suggests that elective 
versus non- elective status might be a valuable covariable 
in PRAIS-2, but large cohorts with these data would be 
needed to determine this.
A strength of the present study is that data were prospec-
tively collected as part of the NCHDA national audit. As 
such, they have undergone continuous and inclusive 
systematic validation, which includes the review of a 
sample of case notes by external auditors to ensure coding 
accuracy.12 A key limitation of this study is that the sample 
size is relatively small and considerably smaller than the 
cohort used to develop PRAIS-2, which included a total 
of 21 838 procedures (combining development and vali-
dation). Further, 10.5% of procedures had missing data 
on mortality and/or variables used to calculate PRAIS-2. 
These individuals tended to have higher risk profiles and 
their mortality rates were higher. Unlike the development 
cohort that included all UK patients, we only have data 
from one centre located in the South West of England 
where the population are more affluent and less ethni-
cally mixed in comparison to the UK as a whole. Hence, 
further replication in a larger and more diverse popula-
tion is necessary.
The Hosmer and Lemeshow goodness of fit test for 
calibration is widely used in assessing calibration,27 28 but 
it provides a statistical test result comparing predicted 
to observed outcome rates across arbitrary grouping of 
deciles of risk, which may have limited clinical applica-
bility. Therefore, we used a recently proposed method 
Table 3 Metrics of model discrimination according to 










Cohort 2 Cut- off 0.001 0.003 0.03 0.07
Sensitivity 1 1 0.69 0.56
Specificity 0.10 0.20 0.80 0.90
PPV 0.02 0.02 0.06 0.10
NPV 1 1 0.99 0.99
LRP 1.11 1.25 3.64 6.20
LRN 0 0 0.37 0.47
LRN, negative- likelihood ratios; LRP, positive- likelihood ratios; 
NPV, negative predictive values; PPV, positive predictive values.
Figure 3 Area under the receiver operating characteristic curve (AUC) in the subset of non- elective procedures in the external 
validation cohort.
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(calibration belt) which does not require patients to 
be categorised but rather compares across the contin-
uous score of risk for our main method of assessing cali-
bration.29 We also presented Hosmer and Lemeshow 
goodness of fit test in the supplementary material for 
comparison with any previous studies.
In conclusion, our study shows good external validity 
of PRAIS-2 for predicting short- term mortality in paedi-
atric cardiac surgery (the outcome it was developed to 
predict). We also show preliminary evidence that PRAIS-2 
accurately predicts short- term mortality in non- elective 
procedures. If similar results were found in more diverse 
external populations, including those outside of the UK, 
its wider adoption for risk prediction in paediatric patients 
undergoing cardiac surgery would be appropriate.
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